

DRUG PRIOR AUTHORIZATION COMMITTEE MEETING
March 15, 2012
615 Howerton Court, 2nd floor
Jefferson City, MO 65109

Committee Members Present

Conrad Balcer, D.O.
Stephen Calloway, RPh
Laine Young-Walker, M.D.
Pat Bryant, PharmD
Gene Forrester, RPh
Morgan Sperry, PharmD, (alternate) – via video conference

MO HealthNet Staff Present:

Rhonda Driver, RPh, Director of Pharmacy
Mark Roaseau, RPh, Clinical Pharmacist
Jayne Zemmer, Program Manager
Jenna Twehus, RN
Mary Heet, RN
Angela Wilson, Unit Supervisor
Marga Hoelscher, Deputy Division Director
Tasia Roberts, Clerical
Whitney Maloy, Clerical

Contractors in Attendance:

Rick Pope, PharmD, First Health Services
Jennifer Kemp-Cornelius, PharmD, ACS
Josh Moore, ACS
Katie Wilbers, ACS

Others Attending:

Lon Lowrey, Novartis	Jared Lurk, Novartis	Sam Smothers, MedImmune	Del Deen, Astra Zeneca
Patricia Grossman, Boehringer-Ingelheim		David Larr, Boehringer-Ingelheim	Dave Sproat, BMS
Rita Lakamp, Sanofi	Terri Hurley, Astra Zeneca	Stephanie Keithly, Novo Nordisk	Stephen Reimann, Sanofi
Jim Baumann, Pfizer	Jennifer Stoffel, Johnson & Johnson	Todd Houldsworth, Johnson & Johnson	
John Valenti, Sanofi	Rick Barbarash, Astra Zeneca	Matt Wessels, Sunovion	Suzanne Goot, Abbott
Eric Blake, Merck	Jessica Hurtis, Novo Nordisk	Jignesh Patel, Novo Nordisk	Dean Groth, Pfizer
Berend Koops, Merck	Scott Edelhauser, Alcon	Jeff Himmelberg, Glaxo Smith Kline	Amir Karimzadeh, Forest
Mike Kloos, Pfizer	Mark Villmann, Asias	Tom O'Donnell, Genetech	Chet Steckle, Purdue

Many names on the sign-in sheet were illegible. Sign in sheet on file for review.

Welcome, Introductions and Opening Remarks	Rhonda Driver, RPh, Director of Pharmacy called the meeting to order. No introductions or announcements were made.
Minutes Approval	Minutes of the December 15, 2011, meeting were reviewed and approved as submitted. Gene Forrester wanted to make one clarification in regards to when the date of the meeting was scheduled. It was determined that date listed on the previous minutes of December 15, 2011, was incorrect. (See Roll Call Vote)
Pharmacy Program/Budget Update	Ms. Hoelscher provided a Budget Update. She stated that we have seen about \$191,000,000.00 worth of general revenue savings which are the monies that the state has the discretion to use as it sees fit. Ms. Hoelscher also stated that there are appropriations for Medicaid in the Department of Social Services' budget, Department of Mental Health, and the Department of Health. Ms. Hoelscher stated that they have budgeted this year for those drugs we anticipate going generic during the next fiscal year. The Drug Rebate Unit has been very successful in getting rebates and this success has helped build the budget. Ms. Hoelscher stated that there have not been any cuts to pharmacy other than what we believe we can save through the pricing process. The budget has to be finalized by June 30.
DUR Report	Rhonda Driver reported the DUR Board reviewed, and concurred with the recommendations made by the Drug Prior Authorization (PA) Committee in December and have been scheduled implementation.
Old Business	
Implementation Schedule	An updated copy of the Proposed Implementation Schedule for Edits, including PDL classes was included in the Members' meeting packet and provided as a handout to all attending. The schedule included the items that were discussed in December and January. They are scheduled for implementation in the next quarter. Narcotic edits have been implemented and a fiscal edit has been done for non-oral contraceptive agents. Schedules may be found on the MHD web page at http://dss.missouri.gov/mhd/cs/pharmacy/impsched.pdf
New Business	Jayne Zemmer provided updates on the Health Home Initiative stating that the programs have been started since January and reviewed what types of Health Homes were approved and Ms. Zemmer went over the requirements for providers and what the enrollment numbers were thus far.
New Drug Review	Discussion – A listing of products recommended for open access, clinical edit, as a preferred drug list (PDL) product, or continued prior authorization was provided in the Members' meeting packet for discussion and action. This listing was also provided as a handout to all attending. <ul style="list-style-type: none"> • Public Hearing – Eric Blake, Sr. Account Executive, with Merck presented information for the product Juvivync. Asked for consideration to be included on the Preferred Drug List. • Decision – Members voted to accept the new drug recommendations as presented. (See Roll Call Vote)
Clinical Edit (CE) Review:	
Atypical Anti Psychotics - Clinical Edit	<ul style="list-style-type: none"> • Discussion –Ms. Driver reviewed the criteria document noting that the current dosing for some of the drugs is considerably higher than FDA approval dosing. • Public Hearing-No comments were entered. • Decision – The Committee voted to accept this edit as presented. (See Roll Call Vote)

SNRI-Clinical Edit	<ul style="list-style-type: none"> • Discussion – Ms. Driver reviewed the criteria document noting that the current dosing for some of the drugs is considerably higher than FDA approval dosing. • Public Hearing-No comments were entered. • Decision –The Committee voted to accept this edit as presented. (See Roll Call Vote)
SSRI-Clinical Edit	<ul style="list-style-type: none"> • Discussion – Ms. Driver reviewed the criteria document noting that the current dosing for some of the drugs is considerably higher than FDA approval dosing. • Public Hearing-No comments were entered. • Decision – The Committee voted to accept this edit as presented. (See Roll Call Vote)
PDL Annual Review:	
BPH Agents-PDL	<ul style="list-style-type: none"> • Discussion – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents. The Cialis approval and denial criteria were reviewed to determine if any changes should be made. • Public Hearing-No comments were entered. • Decision – The Committee voted to accept this edit with the caveat that the Cialis component can be re-reviewed at a later date. (See Roll Call Vote)
Anticoagulant Agents-PDL (Oral & Subcutaneous)	<ul style="list-style-type: none"> • Discussion – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents. Mr. Roaseau also stated that the anticoagulant agents combined the platelet aggregate inhibitors, the low molecular weight heparins, and the anti-thrombin inhibiting agents. It was determined that the proposal may need to be re-reviewed to allow patients who have not had the aspirin therapy previously access to the items on the preferred list. • Public Hearing-Patti Grossman, PharmD with Boehringer-Ingelheim, presented Pradaxa. Jawad Wunej, PharmD with Eli Lilly, presented Effient. Jennifer Stoffel, with Janssen Scientific Affairs, presented Xarelto. Terri Hurley, RN with AstraZeneca, presented Brilinta. • Decision – The Committee voted to accept this edit with the addition of criteria arm for use of Demeclocycline as first-line for treatment of SIADH. (See Roll Call Vote)
Antiemetics Agents-PDL	<ul style="list-style-type: none"> • Discussion – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents. Ms. Driver stated that other than the specific criteria for the outlier products that have very specific indications, there is no change to this edit. • Public Hearing-No comments were entered. • Decision – The Committee voted to accept this edit as presented. (See Roll Call Vote)
Topical Benzoyl Peroxide/ Clindamycin Combination-PDL	<ul style="list-style-type: none"> • Discussion – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing-No comments were entered. • Decision – The Committee voted to accept this edit as presented. (See Roll Call Vote)
Beta Adrenergic Agents Long Acting-PDL	<ul style="list-style-type: none"> • Discussion – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents, stating that because of supplementals and pricing, Serevent Diskus is being moved to a non-preferred status. • Public Hearing- Jared Lurk, Associate Director with Novartis Drug, presented Arcapta. • Decision – The Committee voted to accept this edit with the recommendation to add Arcapta to the non-

	preferred agents. (See Roll Call Vote)
Beta Adrenergic Agents Nebulized-PDL	<ul style="list-style-type: none"> • Discussion – Ms. Driver reviewed the criteria document, and reviewed the preferred and non-preferred agents noting that the recommendation was to move Accuneb from non-preferred to preferred. • Public Hearing- Nicole with Nephron Pharmaceuticals requested that the low-dose Albuterol stay preferred rather than non-preferred. • Decision – The Committee voted to accept this edit as presented. (See Roll Call Vote)
Beta Adrenergic Agents Short Acting-PDL	<ul style="list-style-type: none"> • Discussion – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents, noting that Arcapta will have to be removed from this class. • Public Hearing- No comments were entered. • Decision – The Committee voted to accept this edit with the recommendation to remove Arcapta from this class. (See Roll Call Vote)
COPD Agents-PDL	<ul style="list-style-type: none"> • Discussion – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents. Ms. Driver noted that Arcapta will be moved to this class and recommended as non-preferred and Daliresp, new to this class, is also being recommended for non-preferred status. • Public Hearing- Rick Barbarash, PharmD with AstraZeneca, presented on Symbicort. Amir Karimzadeh, PharmD with Forest Research Institute, presented Daliresp. • Decision – The Committee voted to accept this edit as presented. (See Roll Call Vote)
Hematopoietic Agents-PDL	<ul style="list-style-type: none"> • Discussion – Ms. Driver reviewed the criteria document, and noted that all the recommended drugs in this class are preferred. • Public Hearing- No comments were entered. • Decision – The Committee voted to accept this edit as presented. (See Roll Call Vote)
Growth Hormones-PDL	<ul style="list-style-type: none"> • Discussion – Ms. Driver stated that there is no change recommended for this class. • Public Hearing- No comments were entered. • Decision – The Committee voted to accept this edit as presented. (See Roll Call Vote)
Inhaled Corticosteroids-PDL	<ul style="list-style-type: none"> • Discussion – Ms. Driver stated that there is no change recommended for this class. • Public Hearing- No comments were entered. • Decision – The Committee voted to accept this edit as presented. (See Roll Call Vote)
Insulins-PDL	<ul style="list-style-type: none"> • Discussion – Ms. Driver stated that there is no change recommended for this class. • Public Hearing- No comments were entered. • Decision – The Committee voted to accept this edit as presented. (See Roll Call Vote)
Insulins Long Acting-PDL	<ul style="list-style-type: none"> • Discussion – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing- No comments were entered. • Decision – The Committee voted to accept this edit as presented. (See Roll Call Vote)
Insulins Rapid Acting-PDL	<ul style="list-style-type: none"> • Discussion – Ms. Driver stated that there is no change recommended for this class. • Public Hearing- No comments were entered. • Decision – The Committee voted to accept this edit as presented. (See Roll Call Vote)

Insulins Mix-PDL	<ul style="list-style-type: none"> ● Discussion – Ms. Driver stated that there is no change recommended for this class. ● Public Hearing- No comments were entered. ● Decision – The Committee voted to accept this edit as presented. (See Roll Call Vote)
Non Ergot Dopamine Receptor Agonists-PDL	<ul style="list-style-type: none"> ● Discussion – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents, introduction Azilect as a new product that has been recommended for the non-preferred status. ● Public Hearing- No comments were entered. ● Decision – The Committee voted to accept this edit as presented. (See Roll Call Vote)
Ophthalmic NSAIDS-PDL	<ul style="list-style-type: none"> ● Discussion – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents, noting that Durezol is recommended for preferred status and that some of the newer products-Lotemax, Bromfenac, and Bromday-are recommended for non-preferred status. ● Public Hearing- No comments were entered. ● Decision – The Committee voted to accept this edit as presented. (See Roll Call Vote)
Sedative Hypnotics-PDL	<ul style="list-style-type: none"> ● Discussion – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents. Lunesta has been moved to preferred status. Ms. Driver called attention to the lists stating that Temazepam is listed under both preferred and non-preferred, but with different doses. ● Public Hearing- No comments were entered. ● Decision – The Committee voted to accept this edit as presented. (See Roll Call Vote)
Skeletal Muscle Relaxants-PDL	<ul style="list-style-type: none"> ● Discussion – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents. Lorzone was introduced and it is being recommended for non-preferred status; Cyclobenzaprine ER is also being recommended for non-preferred. ● Public Hearing- No comments were entered. ● Decision – The Committee voted to accept this edit as presented. (See Roll Call Vote)
Statins-PDL	<ul style="list-style-type: none"> ● Discussion – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents. ● Public Hearing- No comments were entered ● Decision – The Committee voted to accept this edit with the understanding that once the price of Atorvastatin has been lowered, it will be moved to preferred status. (See Roll Call Vote)
Triglyceride Lowering Agents-PDL	<ul style="list-style-type: none"> ● Discussion – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents. ● Public Hearing- No comments were entered. ● Decision – The Committee voted to accept this edit as presented. (See Roll Call Vote)
Urinary Tract Antispasmodics-PDL	<ul style="list-style-type: none"> ● Discussion – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents. Ms. Driver stated that Oxytrol has been moved to preferred status and Sanctura has been recommended for non-preferred status. ● Public Hearing- No comments were entered. ● Decision – The Committee voted to accept this edit as presented. (See Roll Call Vote)
Preferred Drug List Announcement	A handout of therapeutic categories to be considered for inclusion on the Preferred Drug List for the next phase and meeting was included in the meeting packet. This handout was also provided to all attendees and will be posted to the Division's web page.

ACS Update	<p>Jennifer Kemp-Cornelius, PharmD, reviewed the call center statistics for poly pharmacy and long-acting narcotics. Ms. Kemp-Cornelius went over the denial criteria for long-acting narcotics. Ms. Kemp-Cornelius reviewed the approval criteria for poly pharmacy stating that adults are allowed to have up to five psychotropic medications, while children can have up to three psychotropic medications. Ms. Kemp-Cornelius stated that the system will be triggered at that sixth drug-for adults-but that doesn't automatically mean a denial; per Rhonda Driver, the sixth medication will get the request in the door, but the whole profile/plan of care is under evaluation to determine if the request should be approved or denied. Ms. Kemp-Cornelius stated that the point of this edit is to allow MO HealthNet to have a conversation with the prescriber about the patient's therapy and it forces the prescriber to provide adequate documentation for why they feel this patient needs to be on more than the maximum allowed psychotropic medications.</p>
Program Utilization: Top 25 Drugs by Cost	<p>Jennifer Kemp-Cornelius, PharmD, reviewed the Top 25 Drugs by Cost and provided two forms, one showing by Paid Amount and one by Claims.</p>
Call Center Statistics/ CyberAccess Reports	<p>A handout detailing pharmacy help desk call center activity was provided for all attending. Cyber Access Active User Counts and Logging Information reports detailing activity was shared. Jennifer Kemp-Cornelius stated that the tele-monitoring vendors that are used by MO HealthNet are required to share clinical data with ACS and in turn, ACS is able to put that information into CyberAccess which has a Continuity of Care Document which can now be shipped out.</p>
Adjourn	<p>2:49:00 The meeting was adjourned at approximately 1:00pm. The next meeting of the Drug PA Committee is scheduled for June 21, 2012 and is expected to be held at the Secretary of State Building at 600 West Main Street. Attendees were advised to check the <u>calendar of events</u> on the MHD website for meeting location changes over the next few months. (See attached roll call)</p>

Roll Call Votes – March 15, 2012

Member	Minutes	New Drug Review	Atypical Antipsychotic Clinical Edit	SNRI Clinical Edit	SSRI Clinical Edit	Androgen Hormone Inhibitors (BPH)	Anticoagulant Agents (Oral & Subcutaneous)	Antiemetics – Oral
Conrad Balcer, D.O.	M	M	M	M	M	M	M	S
Pat Bryant, Pharm.D.	S	Y	S	S	S	Y	S	M
Steven Calloway, R. Ph	A	Y	Y	Y	Y	Y	Y	Y
Gene Forrester, R. Ph.	Y	S	Y	Y	Y	S	Y	Y
Laine Young-Walker, M.D.	A	Y	Y	Y	Y	Y	Y	Y

Member	Benzoyl Peroxide/Clindamycin Topical Agents	Beta-Adrenergic Agents: Long Acting	Beta-Adrenergic Agents: Nebulized	Beta Adrenergic Agents: Short Acting	COPD Anticholinergics	Epoetin Agents	Growth Hormones	Inhaled Corticosteroids
Conrad Balcer, D.O.	S	M	M	Y	M	S	S	Y
Pat Bryant, Pharm.D.	M	Y	Y	M	S	Y	Y	Y
Steven Calloway, R. Ph	Y	Y	Y	S	Y	Y	Y	Y
Gene Forrester, R. Ph.	Y	Y	S	Y	Y	M	M	M
Laine Young-Walker, M.D.	Y	S	Y	Y	Y	Y	Y	S

Member	Insulins	Insulins – Long Acting	Insulins – Rapid Acting	Insulins - Mix	Non-Ergot Dopamine Receptor Agonists	Ophthalmic NSAIDS	Sedative Hynotics	Skeletal Muscle Relaxants
Conrad Balcer, D.O.	Y	Y	Y	Y	M	S	M	M
Pat Bryant, Pharm.D.	M	M	M	M	S	Y	Y	S
Steven Calloway, R. Ph	Y	Y	Y	Y	Y	Y	Y	Y
Gene Forrester, R. Ph.	S	S	S	S	Y	M	S	Y
Laine Young-Walker, M.D.	Y	Y	Y	Y	Y	Y	Y	Y

Member	Statins	Triglyceride Lowering Agents	Urinary Tract Antispasmodics	Adjourn
Conrad Balcer, D.O.	M	Y	S	M
Pat Bryant, Pharm.D.	S	S	M	Y
Steven Calloway, R. Ph	Y	Y	Y	Y
Gene Forrester, R. Ph.	Y	M	Y	S
Laine Young-Walker, M.D.	Y	Y	Y	Y